Acetylcholinesterase inhibitors attenuate atherogenesis in apolipoprotein E-knockout mice.

  title={Acetylcholinesterase inhibitors attenuate atherogenesis in apolipoprotein E-knockout mice.},
  author={Keita Inanaga and Toshihiro Ichiki and Ryohei Miyazaki and Kotaro Takeda and Toru Hashimoto and Hirohide Matsuura and Kenji Sunagawa},
  volume={213 1},
OBJECTIVE Donepezil, a reversible acetylcholinesterase inhibitor, improves cognitive function of Alzheimer's disease. Stimulation of cholinergic system was reported to improve long-term survival of rats with chronic heart failure and to attenuate inflammatory response in mice with lipopolysaccharide-induced sepsis. We sought to determine whether the pharmacological stimulation of cholinergic system by donepezil reduces atherogenesis in apolipoprotein (Apo) E-knockout (KO) mice. METHODS AND… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 15 extracted citations

Cholinesterase inhibitors: cardioprotection in Alzheimer's disease.

Journal of Alzheimer's disease : JAD • 2014
View 6 Excerpts
Highly Influenced

MicroRNAs as Potential Mediators for Cigarette Smoking Induced Atherosclerosis

International journal of molecular sciences • 2018
View 1 Excerpt


Publications referenced by this paper.
Showing 1-10 of 30 references

The impact of nitric oxide in cardiovascular medicine : untapped potential utility

F Amenta, C Cavallotti, F Ferrante, M Zomparelli
Am J Med • 2009

4 - Year trial of tiotropium in chronic obstructive pulmonary disease

HarrisonDG Cai H
N Engl J Med • 2008

Efficacy and safety of donepezil , galantamine , and rivastigmine for the treatment of Alzheimer ’ s disease : a systematic review and meta - analysis

M Reale, C Iarlori, F Gambi
Clin Interv Aging • 2008

Similar Papers

Loading similar papers…